



Press Release

For immediate release

CAPLIN POINT'S CRO AMARIS CLINICAL COMPLETES USFDA AUDIT WITH NIL OBSERVATIONS

Chennai, Sep 24, 2021: Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Amaris Clinicals (Amaris), the Clinical Research Organization (CRO) division of Caplin Point Laboratories Limited, located at Chennai, has completed a virtual audit from United States Food and Drug Administration (USFDA) with NIL observations.

Chairman C. C. Paarthipan commented "It is an excellent milestone for our group, and shows our commitment to maintaining the highest standards of quality and compliance at all our units. In addition to being a profit centre on its own in the coming years, Amaris will facilitate cost effective and quicker foray into newer geographies we plan to expand, where BA/BE studies are required for product approvals. Considering the potential increase in demand for these activities, we will be expanding capacities at this site shortly."

The company targets approvals on mutual recognition basis from other regulatory bodies, including ones from Latin America, a key geography for Caplin Point.

ABOUT AMARIS CLINICAL

Amaris Clinical is a highly automated state of the art Clinical Research Organization capable of performing clinical studies for submissions with various Regulators like USFDA, EMA, WHO, TGA, ANVISA, etc. Facilities at Amaris Clinical including SAM HD by Hamilton which is a fully automated sample management system for secured storage of samples along with Watson LIMS. Another first of its kind installation in India is Andrew Alliance Pipetting Robot which eliminates human errors and user fatigue, which are both principal causes of experimental variation. The establishment contains 72-beds as on date, with plans to expand capacities to around 115 beds in future.

ABOUT CAPLIN POINT LABORATORIES LIMITED

Caplin Point Laboratories Limited is a fast-growing pharmaceutical Company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company's Subsidiary Caplin Steriles Limited caters to the Regulated Markets for Injectable and Ophthalmic products.



Caplin Point Laboratories Limited has been selected on Forbes Asia's "200 Best Under a Billion" list 4 times in the last 8 years (2014, 2015, 2016 and 2021), and was recently awarded "The Emerging Company of 2018" and "Business Excellence Award for 2019" by Economic Times.

Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward - looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Caplin Mr. Dinesh R G (Company Secretary) Tel: +91 44 24968000 investor@caplinpoint.net Mr. Rahul Thakur Christensen Advisory rthakur@christensenir.com	Registered Office 3 rd Floor, Ashvich Towers, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai – 600 096, Tamil Nadu, INDIA. Tel : +91 44 2496 8000 CIN: L24231TN1990PLC019053 ISIN: INE475E01026 NSE Code: CAPLIPOINT BSE CODE: 524742 website: www.caplinpoint.net
---	---